Slides Airfinity – 5th GLOBAL BIOPHARMA CEO / TOP EXECS VIRTUAL PRESS BRIEFING – COVID-19 (8 December 2020)

Press release 11 Mar 2025

Pharmaceutical industry issues call for collective action to address the rising global burden of chronic disease

Non-communicable diseases (NCDs) including cancer, diabetes, cardiovascular disease, lung disease, mental health, and neurological disorders are responsible for 75% of deaths worldwide. New research demonstrates that investing an additional 1% of GDP in public healthcare spending, where at least 40% is aimed at preventing and treating NCDs, could save close to 5 million lives each...

Trade and Health Agenda: A Meaningful World Trade Organization Roadmap to Strengthen Global Health

Ahead of the 14th WTO Ministerial Conference (MC14), trade associations representing the pharmaceutical industry provide a perspective on how WTO Members can a roadmap to strengthen global health through meaningful trade policies.

Value of investment on NCDs: Impact on health outcomes in low- and middle-income countries

In new research commissioned by IFPMA, Airfinity has determined that an additional investment of 1% of GDP toward domestic general government health expenditure in low- and middle-income countries (LMICs) would amount to a US$ 310 billion additional investment, representing a 33% increase in current spending. This research is a response to the UHC 2030 action agenda...